Register entry
- Registered sites
- 0
- Active NDC listings
- 22
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
2222 active NDC listings: 16 plasma derivative, 6 human prescription drug. By marketing category: BLA 22.
| Dosage form | NDCs |
|---|---|
| kit | 22 |
| Route | NDCs |
|---|---|
| intravenous | 10 |
| Labeller name on the listing | NDCs |
|---|---|
| bioverativ therapeutics inc. | 22 |
Catalogue
Marketed products
22| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ALPROLIX | Coagulation Factor IX (Recombinant), Fc Fusion Protein | kit | 71104-911BLA |
| ALPROLIX | Coagulation Factor IX (Recombinant), Fc Fusion Protein | kit | 71104-922BLA |
| ALPROLIX | Coagulation Factor IX (Recombinant), Fc Fusion Protein | kit | 71104-933BLA |
| ALPROLIX | Coagulation Factor IX (Recombinant), Fc Fusion Protein | kit | 71104-944BLA |
| ALPROLIX | Coagulation Factor IX (Recombinant), Fc Fusion Protein | kit | 71104-966BLA |
| ALPROLIX | Coagulation Factor IX (Recombinant), Fc Fusion Protein | kit | 71104-977BLA |
| ALTUVIIIO | Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl | kit | 71104-978BLA |
| ALTUVIIIO | Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl | kit | 71104-979BLA |
| ALTUVIIIO | Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl | kit | 71104-981BLA |
| ALTUVIIIO | Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl | kit | 71104-982BLA |
| ALTUVIIIO | Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl | kit | 71104-983BLA |
| ALTUVIIIO | Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl | kit | 71104-984BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-801BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-802BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-803BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-804BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-805BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-806BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-807BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-808BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-809BLA |
| ELOCTATE | Antihemophilic Factor (Recombinant), Fc Fusion Protein | kit, intravenous | 71104-810BLA |
Enquiry
Common questions
- Is Bioverativ Therapeutics Inc. FDA approved?
- Bioverativ Therapeutics Inc. holds no registered establishment of its own; 22 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Bioverativ Therapeutics Inc. make?
- 22 products are listed under Bioverativ Therapeutics Inc. in the openFDA NDC Directory, most often as kit. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.